Large-scale Production of Recombinant RNAs on a Circular Scaffold Using a Viroid-derived System in Escherichia coli
November 30th, 2018
8.8K views
Here, we present a protocol to produce large amounts of recombinant RNA in Escherichia coli by co-expressing a chimeric RNA that contains the RNA of interest in a viroid scaffold and a plant tRNA ligase. The main product is a circular molecule that facilitates purification to homogeneity.
Overview
This article presents a method for producing large amounts of recombinant RNA in Escherichia coli using a chimeric RNA scaffold. The circular RNA produced facilitates purification to homogeneity, making it suitable for various applications.
Key Study Components
Area of Science
- Biotechnology
- Molecular Biology
- RNA Research
Background
- Recombinant RNA is challenging to produce in large quantities.
- Traditional methods often rely on DNA or proteins.
- Escherichia coli is a common host for recombinant production.
- Circular RNA scaffolds can enhance stability and purification.
Purpose of Study
- To develop a scalable method for producing recombinant RNA.
- To utilize a circular RNA scaffold for improved purification.
- To demonstrate the feasibility of using Escherichia coli for RNA production.
Methods Used
- Co-expression of RNA of interest in a circular scaffold.
- Application of a plant tRNA ligase for RNA circularization.
- Utilization of a patented viroid for scaffold design.
- Scaling up the process for large-scale production.
Main Results
- Successful production of circular recombinant RNA.
- Facilitated purification to homogeneity.
- Demonstrated cost-effectiveness of the method.
- Scalable process suitable for research and industrial applications.
Conclusions
- The method provides a reliable way to produce recombinant RNA.
- Circular scaffolds enhance the purification process.
- This approach can significantly benefit RNA research and applications.
Frequently Asked Questions
What is the main advantage of this method?
The main advantage is the cost-effective and scalable production of recombinant RNA in Escherichia coli.
How does the circular RNA scaffold help?
The circular RNA scaffold enhances stability and facilitates purification to homogeneity.
What is the role of the plant tRNA ligase?
The plant tRNA ligase mediates the circularization of the RNA, which is crucial for the method's success.
Is this method applicable for industrial use?
Yes, the method is designed to be easily scaled up for industrial applications.
What type of RNA can be produced using this method?
The method can produce various recombinant RNAs of interest for research or industrial applications.
What organism is used for the RNA production?
Escherichia coli is used as the host organism for producing recombinant RNA.
Executive Industry Relevance
Producing recombinant RNA at scale remains a bottleneck for RNA-based therapeutic and diagnostic development. This method enables cost-effective, high-yield production in E. coli using a circular viroid-derived scaffold, improving purification efficiency and batch consistency. The approach supports early-stage discovery workflows by providing reliable access to structurally defined RNA molecules for functional screening and mechanistic studies.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables production of recombinant RNAs for target engagement assays and functional validation in cellular systems.
- Operational Value: Reduces dependency on costly in vitro transcription or mammalian expression systems for early RNA reagent generation.
Screening & Assay Development
- Scientific Value: Generates homogeneous circular RNA populations suitable for standardized binding and activity assays.
- Operational Value: Facilitates assay reproducibility through consistent RNA quality and reduced batch variability.
Translational & Preclinical Research
- Scientific Value: Supports production of modified RNAs (e.g., labeled or tagged variants) for biodistribution and mechanism-of-action studies.
- Operational Value: Enables scalable supply for preclinical toxicology and pharmacokinetic evaluations requiring gram-scale RNA material.
Pipeline & Workflow Integration
The method fits within the discovery-to-preclinical continuum, providing a scalable upstream process for RNA reagent generation prior to functional screening and lead optimization.
- Discovery Biology: Supports hypothesis testing by enabling rapid production of wild-type and mutant RNA constructs for structure-function analysis.
- Screening: Delivers assay-ready RNA with high purity, reducing false positives from heterogeneous preparations.
- Analytics: Yields quantifiable, circular RNA fractions amenable to quantification by capillary electrophoresis or qPCR-based methods.
- Translational Research: Provides material for pharmacokinetic profiling and target validation in disease-relevant models.
- Enterprise Reuse: Establishes a reusable platform for generating diverse RNA ligands, aptamers, or regulatory elements across multiple projects.
Operational & Enterprise Impact
- Scientific Value: Improves predictive confidence in RNA-target interactions by minimizing heterogeneity-related artifacts.
- Operational Value: Employs standard E. coli fermentation and purification infrastructure, lowering technical barriers to adoption.
- Strategic Value: Reduces cost and timeline for RNA reagent production, accelerating hit-to-lead progression.
- Portfolio Impact: Enables risk-adjusted investment in RNA-targeted programs by ensuring reliable reagent supply.
Implementation Considerations
- Requires molecular cloning expertise for cDNA insertion into the viroid scaffold.
- Depends on access to standard laboratory equipment: thermocycler, electrophoresis systems, centrifuges, and liquid chromatography.
- Necessitates coordination between molecular biology and analytical teams for construct validation and RNA quality assessment.
- Adaptation may be needed for RNAs exceeding optimal size limits for efficient circularization and yield.
- Yield variability based on insert size necessitates small-scale optimization prior to scale-up.
Biopharma FAQs
Why does circular RNA improve purification?
Circular RNA resists exonuclease degradation and migrates distinctly in gels, enabling separation from linear host RNA contaminants. This property allows purification to near homogeneity using standard chromatographic and electrophoretic methods.
How does co-expression of tRNA ligase enable RNA circularization?
The plant tRNA ligase catalyzes the phosphodiester bond formation between the 5' phosphate and 3' hydroxyl ends of the viroid-derived RNA transcript, resulting in a stable circular recombinant RNA molecule.
What quantitative yield supports scalability?
The method produces tens of milligrams of recombinant RNA per liter of bacterial culture under standard laboratory conditions, demonstrating feasibility for scale-up in shake flasks or bioreactors.
Why is host RNA background a challenge in recombinant RNA production?
Host E. coli RNA complicates downstream purification due to abundance and similarity in size, reducing yield and purity of target RNA; circularity provides a biophysical handle to isolate the product.
What analytical step confirms circular RNA formation?
Two-dimensional polyacrylamide gel electrophoresis under denaturing conditions separates circular from linear RNA isoforms, with the circular fraction appearing as a distinct, major band in the gel.
